{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:11Z","timestamp":1786985051838,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.bbrc.2021.02.038","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T22:01:45Z","timestamp":1614290505000},"page":"148-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["CNR1 may reverse progesterone-resistance of endometrial cancer through the ERK pathway"],"prefix":"10.1016","volume":"548","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3268-2029","authenticated-orcid":false,"given":"Fei","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshui","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbrc.2021.02.038_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1470-2045(19)30595-9","article-title":"Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study","volume":"21","author":"Koo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9484","key":"10.1016\/j.bbrc.2021.02.038_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(05)67063-8","article-title":"Endometrial cancer","volume":"366","author":"Amant","year":"2005","journal-title":"Lancet (London, England)"},{"issue":"10023","key":"10.1016\/j.bbrc.2021.02.038_bib3","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.bbrc.2021.02.038_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1634\/theoncologist.2013-0445","article-title":"Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer","volume":"20","author":"Park","year":"2015","journal-title":"Oncol."},{"issue":"6","key":"10.1016\/j.bbrc.2021.02.038_bib5","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.fertnstert.2009.06.013","article-title":"Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium","volume":"92","author":"Yu","year":"2009","journal-title":"Fertil. Steril."},{"issue":"1","key":"10.1016\/j.bbrc.2021.02.038_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2004.06.045","article-title":"Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review","volume":"95","author":"Ramirez","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.bbrc.2021.02.038_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1210\/er.2012-1043","article-title":"Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer","volume":"34","author":"Kim","year":"2013","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.bbrc.2021.02.038_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ygyno.2018.12.018","article-title":"Endocrine therapy in endometrial cancer: an old dog with new tricks","volume":"153","author":"Jerzak","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"2 Suppl","key":"10.1016\/j.bbrc.2021.02.038_bib9","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.ygyno.2008.07.056","article-title":"Sparing fertility in young patients with endometrial cancer","volume":"111","author":"Chiva","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"19","key":"10.1016\/j.bbrc.2021.02.038_bib10","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2006.08.8344","article-title":"Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women","volume":"25","author":"Ushijima","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbrc.2021.02.038_bib11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.mce.2011.10.035","article-title":"Mechanisms of endometrial progesterone resistance","volume":"358","author":"Al-Sabbagh","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bbrc.2021.02.038_bib12","first-page":"381","article-title":"Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma","volume":"7","author":"Shao","year":"2013","journal-title":"Ecancermedicalscience"},{"issue":"8","key":"10.1016\/j.bbrc.2021.02.038_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.tem.2018.05.006","article-title":"Progesterone resistance in endometriosis: an acquired property?","volume":"29","author":"McKinnon","year":"2018","journal-title":"Trends Endocrinol. Metabol."},{"issue":"9","key":"10.1016\/j.bbrc.2021.02.038_bib14","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1002\/cam4.2317","article-title":"DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma","volume":"8","author":"Zhou","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.bbrc.2021.02.038_bib15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.phrs.2017.11.030","article-title":"Phytochemicals as inhibitors of NF-\u03baB for treatment of Alzheimer\u2019s disease","volume":"129","author":"Seo","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.bbrc.2021.02.038_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030525","article-title":"Cannabinoids and hormone receptor-positive breast cancer treatment","volume":"12","author":"Dobovi\u0161ek","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.bbrc.2021.02.038_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050708","article-title":"Down-regulation of cannabinoid type 1 (CB1) receptor and its downstream signaling pathways in metastatic colorectal cancer","volume":"11","author":"Tutino","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bbrc.2021.02.038_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejca.2008.10.010","article-title":"A\u00a0high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer","volume":"45","author":"Chung","year":"2009","journal-title":"Eur. J. Canc."},{"issue":"5","key":"10.1016\/j.bbrc.2021.02.038_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tem.2018.03.001","article-title":"Regulation of adipose tissue metabolism by the endocannabinoid system","volume":"29","author":"van Eenige","year":"2018","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.bbrc.2021.02.038_bib20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fonc.2019.00430","article-title":"Identification of novel predictive biomarkers for endometrial malignancies: N-acylethanolamines","volume":"9","author":"Ayakannu","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.bbrc.2021.02.038_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2012.07.002","article-title":"Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance","volume":"16","author":"Tam","year":"2012","journal-title":"Cell Metabol."},{"issue":"9","key":"10.1016\/j.bbrc.2021.02.038_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092109","article-title":"Role of cannabinoid receptor type 1 in insulin resistance and its biological implications","volume":"20","author":"Nagappan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2021.02.038_bib23","doi-asserted-by":"crossref","first-page":"108712","DOI":"10.1016\/j.biopha.2019.108712","article-title":"Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression","volume":"113","author":"Jiang","year":"2019","journal-title":"Biomedicine & pharmacotherapy\u00a0= Biomedecine & pharmacotherapie"},{"issue":"3","key":"10.1016\/j.bbrc.2021.02.038_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ijc.31913","article-title":"The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk","volume":"144","author":"MacKintosh","year":"2019","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.bbrc.2021.02.038_bib25","doi-asserted-by":"crossref","first-page":"41404","DOI":"10.1038\/srep41404","article-title":"Cholesterol synthetase DHCR24 induced by insulin aggravates cancer invasion and progesterone resistance in endometrial carcinoma","volume":"7","author":"Dai","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bbrc.2021.02.038_bib26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/1471-0528.16108","article-title":"Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial","volume":"127","author":"Yang","year":"2020","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.bbrc.2021.02.038_bib27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/annonc\/mdv539","article-title":"Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer","volume":"27","author":"Mitsuhashi","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbrc.2021.02.038_bib28","doi-asserted-by":"crossref","first-page":"36.e1","DOI":"10.1016\/j.ajog.2012.05.012","article-title":"Biomarkers of progestin therapy resistance and endometrial hyperplasia progression","volume":"207","author":"Upson","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6456","key":"10.1016\/j.bbrc.2021.02.038_bib29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aaw5937","article-title":"Membrane-associated periodic skeleton is a signaling platform for RTK transactivation in neurons","volume":"365","author":"Zhou","year":"2019","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bbrc.2021.02.038_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Canc. Cell"},{"issue":"9","key":"10.1016\/j.bbrc.2021.02.038_bib31","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.tips.2020.06.010","article-title":"Structural and functional insights into cannabinoid receptors","volume":"41","author":"Li","year":"2020","journal-title":"Trends Pharmacol. Sci."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21002266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21002266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:02:38Z","timestamp":1757764958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X21002266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":31,"alternative-id":["S0006291X21002266"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.02.038","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CNR1 may reverse progesterone-resistance of endometrial cancer through the ERK pathway","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.02.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}